Physician profile
Manoj Bhandari
NPI 1720312788
$2,740.62
in general payments reported to CMS, 2019-2025
22 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.86 · 2020: $102 · 2021: $63.20 · 2022: $259 · 2023: $731 · 2024: $875 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $688.86 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.90 | 2020-2025 | Jardiance |
| Pfizer INC. | $293.30 | 2023-2025 | |
| Philips North America LLC | $257.34 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, Diagnostic Ecg Service, (Ck4) Mcot |
| Boston Scientific Corporation | $197.46 | 2023-2025 | Watchman Access System, Watchman, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $138.95 | 2019-2025 | |
| Edwards Lifesciences Corporation | $129.05 | 2023 | Pascal |
| Impulse Dynamics (USA) INC. | $109.98 | 2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.67 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $88.83 | 2023-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $66.10 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $56.39 | 2022-2024 | Farxiga, Wainua |
| Bridgebio Pharma, INC. | $37.08 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $35.22 | 2024 | Arcalyst |
| Novo Nordisk INC | $27.80 | 2025 | Wegovy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $24.54 | 2023 | Arcalyst |
| Shockwave Medical, INC | $23.85 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $21.71 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.67 | 2025 | |
| Vital Connect, INC | $16.74 | 2024 | Vitalpatch Rtm |
| Merck Sharp & Dohme LLC | $14.86 | 2023 | Verquvo |
| Medtronic, INC. | $14.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.